ALKS Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals PLC has a net margin of 24.43% compared to Alkermes PLC's net margin of 20.39%. Alkermes PLC's return on equity of 26.09% beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.

Alkermes PLC has a consensus price target of $34.50, signalling upside risk potential of 18.41%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 47.23%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.492, which suggesting that the stock is 50.793% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $378.1M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $92.4M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, Alkermes PLC's price-to-earnings ratio is 14.75x while Jazz Pharmaceuticals PLC's PE ratio is 17.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.24x versus 2.04x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Mallinckrodt PLC has a net margin of 24.43% compared to Alkermes PLC's net margin of -5.18%. Alkermes PLC's return on equity of 26.09% beat Mallinckrodt PLC's return on equity of -287.81%.

Alkermes PLC has a consensus price target of $34.50, signalling upside risk potential of 18.41%. On the other hand Mallinckrodt PLC has an analysts' consensus of -- which suggests that it could fall by --. Given that Alkermes PLC has higher upside potential than Mallinckrodt PLC, analysts believe Alkermes PLC is more attractive than Mallinckrodt PLC.

Alkermes PLC has a beta of 0.492, which suggesting that the stock is 50.793% less volatile than S&P 500. In comparison Mallinckrodt PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mallinckrodt PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Mallinckrodt PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $378.1M, which are smaller than Mallinckrodt PLC quarterly revenues of $505.5M. Alkermes PLC's net income of $92.4M is higher than Mallinckrodt PLC's net income of -$26.2M. Notably, Alkermes PLC's price-to-earnings ratio is 14.75x while Mallinckrodt PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.24x versus 0.00x for Mallinckrodt PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of 24.43% compared to Alkermes PLC's net margin of 15.11%. Alkermes PLC's return on equity of 26.09% beat Medtronic PLC's return on equity of 8.54%.

Alkermes PLC has a consensus price target of $34.50, signalling upside risk potential of 18.41%. On the other hand Medtronic PLC has an analysts' consensus of $96.00 which suggests that it could grow by 20.59%. Given that Medtronic PLC has higher upside potential than Alkermes PLC, analysts believe Medtronic PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.492, which suggesting that the stock is 50.793% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.820, suggesting its less volatile than the S&P 500 by 17.999%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.51% to investors and pays a quarterly dividend of $0.70 per share. Alkermes PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alkermes PLC quarterly revenues are $378.1M, which are smaller than Medtronic PLC quarterly revenues of $8.4B. Alkermes PLC's net income of $92.4M is lower than Medtronic PLC's net income of $1.3B. Notably, Alkermes PLC's price-to-earnings ratio is 14.75x while Medtronic PLC's PE ratio is 24.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.24x versus 3.16x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of 24.43% compared to Alkermes PLC's net margin of -1.93%. Alkermes PLC's return on equity of 26.09% beat Perrigo Co PLC's return on equity of -3.43%.

Alkermes PLC has a consensus price target of $34.50, signalling upside risk potential of 18.41%. On the other hand Perrigo Co PLC has an analysts' consensus of -- which suggests that it could grow by 41.56%. Given that Perrigo Co PLC has higher upside potential than Alkermes PLC, analysts believe Perrigo Co PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.492, which suggesting that the stock is 50.793% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.517, suggesting its less volatile than the S&P 500 by 48.32%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.37% to investors and pays a quarterly dividend of $0.28 per share. Alkermes PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -1178.74% of its earnings as a dividend.

Alkermes PLC quarterly revenues are $378.1M, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $92.4M is higher than Perrigo Co PLC's net income of -$21M. Notably, Alkermes PLC's price-to-earnings ratio is 14.75x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.24x versus 0.79x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.